National and Kapodistrian University of Athens
Μελέτη παραγόντων κινδύνου για καρδιαγγειακή νόσο σε παιδιά με επιληψία που βρίσκονται σε μακροχρόνια αγωγή με λεβετιρασετάμη
Abstract
dc:descriptionΤhe purpose of the study was to investigate prospectively the short and long-term effect of levetiracetam monotherapy on serum lipids levels, serum total homocysteine and thyroid gland function in epileptic children and whether it increases their cardiovascular risk. Material and methods: We studied 32 epileptic children (18 females and 14 males),with mean age 5,94 ± 4,1 years, treated for new onset epilepsy with levetiracetam monotherapy. Apart from epilepsy, all patients had normal growth, normal liver and renal function and absence of any other medication or prior antiepileptic medication. Serum total cholesterol (TC), High-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C), Triglycerides (TGs), Apolipoprotein A-I (apo A-I),Apolipoprotein B (apo B), Lipoprotein (a) [Lp(a)], Free thyroxine (FT4), Thyrotropin (TSH), Folate (s-F), Vitamin B-12 (s-B12) and serum total homocysteine (p-tHcy), were evaluated before, at 2, 6 and 12 months of levetiracetam monotherapy. We also obtained full blood count and biochemical markers. Dropouts due to the need for other antiepileptic treatment and missing data reduced the initial sample size to 25 patients at 6 months and 20 patients at 12 months of levetiracetam treatment. Results: TGs and TGs/HDL-C ratio were significantly decreased at 6 (p=0.030 andp=0.027, respectively) and 12 months (p=0.001 and p=0.003, respectively) of levetiracetam treatment. LDL-C/HDL-C ratio was significantly decreased at 12 months of levetiracetam treatment. Serum total homocysteine was significantly decreased at 2 months of treatment(p=0.031), while no significant alterations where detected in the vitamin B12 or folic acid level during the study period. Thyroid hormones showed no alterations during the study period.We also found that lymphocyte count was significantly decreased at 6 and 12 months of LEV treatment (p=0.019, p=0.003 respectively). Four children at 6 months of age and three children at 12 months of treatment had lymphocyte count below 10th percentile for age. Μore over, we found significant reduction in uric acid concentration at 6 months after levetiracetam initiation (p=0.02), and ALP was increased after 2 and 6 months of levetiraceram treatment (p=0.005, p=0.007 respectively). Both alterations seem to be 71 transient. No other significant alterations where noted in the other parameters evaluatedduring the study period. Conclusions: Levetiracetam does not cause adverse alterations on blood lipids, homocysteine or thyroid hormones and does not increase the long-term cardiovascular risk for epileptic children taking levetiracetam. Τherefore, levetiracetam may be considered as a safer alternative drug for the prevention or antiepileptic drug-induced cardiovascular complications in adult life.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Paschalidou, Maria
- Πασχαλίδου, Μαρία
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45452